Clinical Trial – NANO SOMA

INPACTS-CORE

Impact of NANO SOMA on Participant-Assessed COVID-19 Treatment Sequelae — Clinically Observed Reported Effects

Study will be limited to participants in the United States

    Participant Application

    Medical History

    COVID-19 Injection History (list all) Provide as much information as possible, please

    Current Health Conditions and Conditions

    Pain/Discomfort/Distress/Limitation at its worst (Choose rating below)
    Pain/Discomfort/Distress/Limitation at its best (Choose rating below)

    Study Participation

    Are you willing to participate in a Study
    Consent
    Disclaimer

    Rima E. Laibow, MD, the Principal Investigator, is a licensed MD but offers no medical advice, consultation or treatment to study participants prior to or during the study. Dr. Laibow has a financial interest in NANO SOMA since she is a paid consultant to the company marketing NANO SOMA. Her personal and clinical experience with NANO SOMA has led her to believe that it may offer unique health benefits and she has designed this Study to test that hypothesis in a population of people for whom little effective help is currently available.
    No representations of cure, assistance, relief or positive outcome is made by either Dr. Laibow, NANO SOMA or the sponsoring organization.